Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes-Reference-Cited by-同舟云学术

Novel hepato-preferential basal insulin peglispro (BIL) does not differentially affect insulin sensitivity compared with insulin glargine in patients with type 1 and type 2 diabetes

Published:2017-02-07 Issue:4 Volume:19 Page:482-488
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Porksen Niels¹,Linnebjerg Helle¹,Garhyan Parag¹,Lam Eric C. Q.²,Knadler Mary P.¹,Jacober Scott J.¹,Hoevelmann Ulrike³,Plum-Moerschel Leona³,Watkins Elaine⁴,Gastaldelli Amalia⁵^ORCID,Heise Tim³

Affiliation:

1. Eli Lilly and Company, Departments of endocrinology, clinical pharmacology, PK/PD and drug disposition Indianapolis; Indiana

2. Lilly-NUS Centre for Clinical Pharmacology, Department of Statistics; Singapore Singapore

3. Profil; Neuss, Germany

4. Profil Institute for Clinical Research, Chula Vista, California

5. Cardiometabolic Risk Unit; Institute of Clinical Physiology; National Research Council (CNR), Pisa Italy

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12834/fullpdf

Reference21 articles.

1. Basal insulin peglispro: overview of a novel long-acting insulin with reduced peripheral effect resulting in a hepato-preferential action;Jacober;Diabetes Obes Metab,2016

2. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus;Sinha;Diabetes Obes Metab,2014

3. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects;Henry;Diabetes Care,2014

4. Basal insulin peglispro (BIL) demonstrates hepato-preferential action vs. insulin Glargine (GL) in patients with type 1 diabetes mellitus (T1DM);Mudaliar;Diabetes,2015

5. A randomized, controlled study of once daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes;Bergenstal;Diabetes Care,2012